Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Pie And Ice Cream !!!

<< Previous

Bullboard Posts

Next >>

Comment by PTBaileyon Apr 05, 2022 8:40am

157 Views

Post# 34575963

RE:Pie And Ice Cream !!!

LOL, I think it will climb, and lets do a little stronger than bubbly.

I am confident they have other announcements in the pipeline ready to go. There would have been no point in announcing anything without phase 1 first, since without phase 1 anything else they would have had no effect and just been met with skepticism due to loss of perceived credibility with so many delays.

One key line in the NR that stood out to me was, "Claritas has already begun outreach to pharmaceutical companies in the PAH space and is in discussions with two such companies."

<< Previous

Bullboard Posts

Next >>

The Market Online’s Weekly Cannabis Report – Nov. 22, 2024